MZ 5-156

Also Known As:

MZ-5-156; PhAc-(Arg(2),Phe(4-Cl),Abu(15),Nle(27))hGH-RH(1-28)Agm; PhAc-2-Arg-6-Phe(4-Cl)-15-Abu-27-Nle-hGH-RH(1-28)Agm; human GH-RH(1-28)agmatine, phenylacetyl-arginyl(2)-4-chlorophenylalanyl(6)-2-aminobutyryl(15)-norleucyl(27)-; human GHRH(1-28)agmatine, phenylacetyl-Arg(2)-4-chloro-Phe(6)-Abu(15)-Nle(27)-

Networked: 17 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Schally, Andrew V: 6 articles (09/2012 - 07/2005)
2.	Schally, A V: 6 articles (06/2008 - 01/2000)
3.	Barabutis, Nektarios: 4 articles (09/2012 - 05/2010)
4.	Siejka, Agnieszka: 4 articles (09/2012 - 05/2010)
5.	Halmos, G: 4 articles (05/2001 - 01/2000)
6.	Varga, J L: 4 articles (05/2001 - 03/2000)
7.	Armatis, P: 3 articles (05/2001 - 01/2000)
8.	Groot, K: 3 articles (05/2001 - 01/2000)
9.	Hebert, F: 2 articles (07/2000 - 01/2000)
10.	Chen, Xuehui: 1 article (01/2012)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2000 - "Exposure in vitro to GH-RH antagonists MZ-5-156 or JV-1 -36 at 1 microM concentration for 24 hours decreased the tumorigenicity of U-87MG cells in nude mice by 10% to 30% and extended the latency period for the development of subcutaneous palpable tumors by 31% to 56%, as compared with the controls. " 05/01/2000 - "After 4 weeks of therapy with MZ-5-156 or JV-1 -36 at the dose of 20 microg/day per animal, the final volume of subcutaneous U-87MG tumors was significantly (P < .01) decreased by 84% and 76%, respectively, as compared with controls. " 07/26/2005 - "Treatment with MZ-5-156 and MZ-J-7-138 significantly (P < 0.05) inhibited the growth of RL and HT tumors by 59.9-73.9%. " 07/01/2000 - "Nude mice implanted with PC-3 tumors received GHRH antagonists MZ-5-156 or JV-1-38, each at 20 microgram/day s.c. " 01/01/1999 - "Various human cancer cell lines were exposed to human GHRH(1-29)NH2 (2-20 nM) or VIP (0.1-5 nM) repeatedly for 12 min or continuously for 96 min. GHRH antagonist MZ-5-156 at 100 to 200 nM concentration inhibited the GHRH- or VIP-induced cAMP release from mammary (MDA-MB-468), prostatic (PC-3), and pancreatic (SW-1990 and CAPAN-2) cancer cells. "
2.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/01/1996 - "The purpose of this study was to investigate the effects of two potent antagonists of growth hormone-releasing hormone (GH-RH), MZ-4-71 and MZ-5-156 on the growth of the H69 human small cell lung cancer (SCLC) and H157 non-SCLC (NSCLC) lines transplanted into nude mice or cultured in vitro. "
3.	Endometrial Neoplasms (Endometrial Cancer) 03/01/2008 - "The objective of this study was the investigation of direct anti-proliferative effect of GHRH antagonist MZ-5-156 on HEC-1A human endometrial cancer cell line and the elucidation of underlying mechanisms. " 03/01/2008 - "These results demonstrate that MZ-5-156 can directly inhibit the proliferation of human endometrial cancer cells, which express mRNA for GHRH and SV1 of GHRH receptor, presumably through the induction of p53-dependent apoptosis coupled with the up-regulation of Fas, phospho-p53 (Ser46), p53AIP1, and caspase-8, -9, and -3, and the down-regulation of Bcl-2."
4.	Carcinoid Tumor (Carcinoid) 09/01/2012 - "In the present study we investigated the in vitro effect of GHRH antagonist, MZ-5-156, on focal adhesion kinase (FAK) activity, on the expression of MMP-2 and MMP-9 metalloproteinases, as well as on vascular endothelial growth factor (VEGF) levels in A549 non-small cell lung (NSCLC) cancer cells and H727 bronchial carcinoid cells. "
5.	Lung Neoplasms (Lung Cancer) 09/01/2012 - "We demonstrate for the first time that GHRH antagonist, MZ-5-156, inhibits FAK signaling in lung cancer cells and decreases the expression of additional factors involved in angiogenesis and invasion. " 11/01/2011 - "GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells."

Related Drugs and Biologics

1.	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
2.	Cyclooxygenase 2 (Cyclooxygenase-2)
3.	Peptides (Polypeptides)
4.	Enzymes
5.	Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)
6.	MZ 4-71
7.	JV 1-36
8.	Focal Adhesion Protein-Tyrosine Kinases
9.	Metalloproteases (Metalloproteinases)
10.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

Related Therapies and Procedures

1.	Therapeutics